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Background: Evidence suggests that poor recruitment into clinical trials rests on a patient ‘deficit’ model – an
inability to comprehend trial processes. Poor communication has also been cited as a possible barrier to
recruitment. A qualitative patient interview study was included within the feasibility stage of a phase III
non-inferiority Randomized Controlled Trial (RCT) (SPARE, CRUK/07/011) in muscle invasive bladder cancer. The aim
was to illuminate problems in the context of randomization.
Methods: The qualitative study used a ‘Framework Analysis’ that included ‘constant comparison’ in which
semi-structured interviews are transcribed, analyzed, compared and contrasted both between and within
transcripts. Three researchers coded and interpreted data.
Results: Twenty-four patients agreed to enter the interview study; 10 decliners of randomization and 14 accepters,
of whom 2 subsequently declined their allocated treatment.
The main theme applying to the majority of the sample was confusion and ambiguity. There was little indication
that confusion directly impacted on decisions to enter the SPARE trial. However, confusion did appear to impact on
ethical considerations surrounding ‘informed consent’, as well as cause a sense of alienation between patients and
health personnel.
Sub-optimal communication in many guises accounted for the confusion, together with the logistical elements of a
trial that involved treatment options delivered in a number of geographical locations.
Conclusions: These data highlight the difficulty of providing balanced and clear trial information within the UK
health system, despite best intentions. Involvement of multiple professionals can impact on communication
processes with patients who are considering participation in RCTs. Our results led us to question the ‘deficit’ model
of patient behavior. It is suggested that health professionals might consider facilitating a context in which patients
feel fully included in the trial enterprise and potentially consider alternatives to randomization where complex
interventions are being tested.
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The Randomized Controlled Trial (RCT) has long repre-
sented the gold standard for clinical scientific investiga-
tion, requiring objectivity, validity and fully informed
consent. Phase III trials normally require large numbers
of participants to detect clinically meaningful differences
[1,2]. Complex RCTs can present difficulties, to the
extent that low levels of recruitment can cause individ-
ual trials to close prematurely [3-5].
Few studies examine how to compare radical surgery
to a relatively non-invasive treatment, such as radical
radiotherapy [6]. The nature of the organizational con-
text and everyday working practices of trial personnel
that may influence precision, validity and accrual rates
of RCTs are seldom focused on [7].
Studies suggesting solutions to poor recruitment in
cancer trials usually do so from the service provider’s
view, premised on a ‘deficit model’ [8]. Patients become
‘the problem’ [8], ‘misunderstanding’ concepts such as
equipoise and randomization [9-11], risks and benefits
of participation [12,13], trial options and procedures in
general [14,15], resulting in a potential violation of the
Declaration of Helsinki [16,17].
Researchers have embedded qualitative studies within
trials to investigate participants’ perspectives [11,18-20].
These and other studies have advised better recruitment
to RCTs by addressing communication [5,15,16,21-23],
physicians’ reluctance to randomize [5,15,23-26], an
inability to describe equipoise [5,11,20], time restraints
[12], physicians’ misconceptions [12], patients’ [5,27] and
physicians’ [5,23] treatment preferences and patients’
trust in their physicians [5,19,20,28-30]. The patient def-
icit model generally persists, however.
This paper focuses on a randomized trial of Selective
bladder Preservation Against Radical Excision (cystec-
tomy) in muscle invasive bladder cancer (SPARE) and
the ways in which perceived trial procedures and com-
municative processes may have affected ‘informed con-
sent’ and forestalled patient participation.The context of the SPARE trial
SPARE (CRUK/07/011) was a phase III non-inferiority
RCT in muscle invasive T2/T3 transitional cell carcin-
oma of the bladder, with an initial feasibility stage to
assess recruitment rates and compliance with assigned
treatment. Embedded within the feasibility stage was
a qualitative patient interview study. The trial wasdesigned in consultation with patient representatives
and approved by the South-East Multicentre Research
Ethics Committee.
Target accrual for the two-year feasibility stage was
110 patients. The main phase III trial would aim to re-
cruit up to 1,015 patients, with an endpoint of overall
survival. Patients aged 18 and over with histologically
confirmed T2/T3 N0 M0 after transitional cell carcin-
oma of the bladder receiving neo-adjuvant gemcitabine-
cisplatin chemotherapy, with satisfactory hematological
profile and liver function tests and who were fit for both
trial treatments were eligible.
Patients were centrally randomized between radical
surgery (cystectomy) following neo-adjuvant chemother-
apy, and selective bladder preservation (SBP) where
definitive treatment (radiotherapy or cystectomy) was
decided based on response to neo-adjuvant chemother-
apy (Figure 1). Consenting patients were randomized be-
tween Day 1, Cycle 2 of chemotherapy and Day 1, Cycle 3.
Participants completed three three-week cycles of neo-
adjuvant chemotherapy, followed by cystoscopy. If the
tumor was down-staged to less than pT2, the patient
then received a fourth cycle of chemotherapy and pro-
ceeded to allocated treatment, that is cystectomy or, if
randomized to SBP, radiotherapy. Without down-staging,
patients in both groups received cystectomy without a
fourth cycle of chemotherapy.
Patient pathway and identification
Patients were referred by General Practitioners (GPs) to
urologists who diagnosed bladder cancer and subse-
quently referred them to clinical oncologists. Due to the
complexity of cancer treatment networks in the UK,
some patients traveled from the diagnosing hospital to
another center for definitive treatment (Figure 2).
Center staff explained the trial and provided informa-
tion sheets that had been carefully scrutinized for patient
acceptability. Patients were given time to consider par-
ticipation. Consent was obtained prior to randomiza-
tion. The qualitative study was designed to illuminate
problems and reasons why patients accepted or declined
randomization.
Methods
The Qualitative Study
Prior to starting definitive treatment, accepters and decli-
ners to randomization were approached and provided
Figure 1 SPARE Trial Schema. TUR – Transurethral resection, EUA – Examination under anaesthetic, TCC – Transitional cell carcinoma,
PS – Performance status, Gem-cis – Gemcitabine – cisplatin chemotherapy, CT – chemotherapy.
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ing an explanation regarding the rationale of the study.
Consent was obtained to pass names and contact details to
the researcher (CM) who contacted patients to ascertain
interest in being interviewed in a venue of their choice,
soon after the invitation to enter the study. Patients who
agreed to participate gave consent and were interviewed
consecutively until no new themes were forthcoming.
Patients were asked: ‘Please tell me about your bladder
cancer experience’ and their perception of trial proce-
dures was explored, including:Randomization and equipoise
Medical terms
Medical procedures
Information given and received
Communication
Decision making
Reasons for accepting or declining
A social scientist (CM), the SPARE trial manager, (RL)
and the SPARE Quality of Life Coordinator, a psycholo-
gist by training (EJ), ‘rated’ and interpreted the patients’
Figure 2 Patient diagnosis and treatment referral pathway.
Table 1 Participant characteristics
Accepters
(n = 12)
Decliners
(n = 10)
Accepters/
Decliners
(n = 2)
Mean age (yrs) 65 (SD 5.6) 71 (SD 5.7) 74 (SD 2.8)
No. males 11 (92%) 7 (70%) 1
Married/Cohabiting 11 (92%) 9 (90%) 1
Upper socio-economic status 9 (75%) 9 (90%) 0
Socioeconomic status is defined according to Office of National Statistics (UK)
categories: 1, 2, 3 NM = non-manual, skilled jobs (Upper Socio Economic
Status); 3, 4, 5 M = manual, unskilled jobs. Retired and unemployed are
categorized as “previous employment” or, when “no job,” are categorized by
employment of head of household.
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standardization. The paper was circulated to all SPARE
authors for comment prior to submission.
Study findings were discussed during regular Trial
Management Group meetings; were disseminated by letter
to trialists and by presentation to SPARE investigators in
an effort to improve informed consent levels and recruit-
ment rates, but no formal assessment was made of how
that information impacted on recruitment procedures.
Method of analysis
Recorded interviews were semi-structured, in line with a
‘Framework Analysis’ [31] that allows for the inclusion
of respondents’ own concerns as well as answering spe-
cific topics. The choice of topics was informed by clin-
ical concerns and previous research in this area of
investigation. Topics were covered in a flexible manner;
patients were probed if they did not arise spontaneously
in the interview. Analysis was an iterative process, allow-
ing for the follow-up of emergent findings. Items were
systematically coded, initially depending on their face value,
followed by conceptual coding leading to over-arching
themes and deviant accounts. The method of constant
comparison was used, where interpretations are made by
checking patients’ perceptions within and across verbatim
transcripts [32]. Interpretation relied on patient context, lit-
erature and field notes. The researchers met regularly to
compare coding and interpretation to ensure reliability.
Disagreements (such as they were) were resolved and at
times, points of discussion were taken to relevant experts
to verify findings. In these cases, the coding framework was
refined and where applicable, reapplied to the data.
Results
SPARE opened in June 2007. In February 2010, with 45
patients recruited, it closed in view of the unfeasibility of
the planned phase III trial due to insufficient eligible
patients [33]. Patient interviews took place between
June 2007 and January 2009, by which time 29 patients(of 114 eligible) had been recruited into SPARE from
12 centers.
A total of 24 patients (21%) were interviewed (Table 1)
– 14 accepters (8 cystectomy, 6 SBP), 2 of whom went
on to decline their randomized treatment (accepter/
decliners – both allocated cystectomy) and 10 decliners,
including 1 patient and his partner, whose comments
were recorded and analyzed together with her husband’s
(Figure 3).
Of participants who had consented to SPARE, five
were interviewed prior to definitive treatment (median
of 13 days before (interquartile range (IQR) -36 to −8)),
eight were interviewed following treatment (median
of 51 days afterwards (IQR 31 to 57)). One patient
was interviewed during radiotherapy treatment. Ethics
approval was not sought to collect treatment details for
patients refusing SPARE; however, the timing of the
interview relative to treatment did not appear to differ
for decliners. The majority were interviewed at home,
across the United Kingdom. Patients’ characteristics
are seen in Table 1. Patients were asked: ‘Please tell me
about your bladder cancer experience’ and probed
to cover the relevant topics while welcoming patients’
own comments.
One overarching theme emerged, namely: ‘Confusion,
ambiguity and alienation: professional and structural dif-
ficulties in communicating to participants’. Sub-themes
included ‘Communicating trial concepts and procedures’,
‘Inter-relational communication’ and ‘Administration
as communication’.
Patients were satisfied with some aspects of their
experience and simultaneously dissatisfied with others.
Satisfaction appeared to lie in respect, trust and connect-
edness with health personnel and the medical enterprise.
‘..he/she’s a (doctor) who instills confidence in you
.. . ..and that is one of the things that was a
consideration when push came to shove and I had to
decide which way it (participation) was going. . ..”
— Mr Brown - Accepter
Figure 3 Qualitative study participant flowchart.
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you can ring them anytime, you have a number that
you can ring day or night just really to talk to
someone. . ..tell them if there is anything that you are
worried about and they will say..’come down’ or
whatever”
— Mrs Sandy - Decliner
All but four participants experienced some aspect
of confusion, including problems with the UK National
Health Service (NHS) structure and general administra-
tion, the design and procedures of the trial, concepts
of randomization, equipoise and personal communica-
tion. Although there was an indication that decliners
to participation were in higher social class categories
(Table 1), there was no consistent association between
patients’ participation, perceived confusion and patient
characteristics.
Communicating trial concepts and procedures
Patients displayed what may be perceived as ‘poor
understanding’ of trial procedures and concepts. This
did not appear to rely on cognition, however. Patients’
accounts suggested that information giving was often
sub-optimal [8] and/or understanding unverified, high-
lighting the crucial role that communication plays in
obtaining ‘informed consent’ [5,11,18-21,29,33-36].There was little that revealed participants’ interpret-
ation of equipoise although there was evidence that
patients and partners who articulated their understand-
ing of the concept had access to the medical enterprise.
“Seeing all the specialists helped me more than I can
say. . .my wife (a medical practitioner) and I asked to see
anyone who might treat me . . .. . .and Dr X indicated
that not enough was known about the two separate
treatments (surgery and radiotherapy). . .and if the chemo
didn’t work I would then go ahead with the surgery.”
— Mr Van - Accepter
An explanation of equipoise was usually perceived to
be absent in the information process, calling for an es-
sential need to validate participants’ understanding prior
to obtaining consent.
“They told me they were doing the trial for
mortality. . .to see who lived longer. . ..but nobody
used the word ‘equipoise’ or that they literally don’t
know which is better. . .”
— Mr Brown - Accepter
The need to believe in expert physicians and an in-
ability to accept medical uncertainty is documented
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in which patient preferences over-ride equipoise and
randomization [5,13,30,36]. Even when trial concepts
are explained (and perceived correctly), patients may
reject advice for personal but rational reasons [37].
Below, Mr Baker voices his incredulity as he faces the
ramifications of uncertainty while striving to maintain
control over his own decision-making in the name of
quality of life.
“He/she told me about the trial. . . It was something
that (the doctors) couldn’t say what the best
(treatment) was. . .I understood the meaning of
balance. . .but I am an active, fit 63 year old man
who travels. . .when I have anything to do with the
medical profession they have said ‘I think . . .this
is the treatment’ ..( ) it was the first time that it
became obvious that somebody wasn’t going to say
that this is the best treatment for you ( ), you are left
to make up your own mind. . .that is how I ended up
going for the radiotherapy ( ) but it was still a
preference rather than knowing it was right ( ) going
into the SPARE trial, this option would be taken
away from you.”
— Mr Baker - Decliner
Below, Mr Plane portrays the uncertainty inherent in
any randomized trial, which often undermines people’s
belief in medical progress. It is for this reason that
randomization was often refused in a context where
surgery was offered against a less radical option.
“. . .it (equipoise) was never explained to me . . .it’s
the first that I have ever heard it. . .and if it had it
would not have changed my mind . . . I will tell you
why because they were doing that sort of surgery
one hundred years ago. . .if they don’t like it chop it
out . . .we have gone a bit further than that these
days and I personally would explore lots of other
routes.”
— Mr Plane - Decliner
Physicians find the concept of equipoise difficult, both
because of personal preference [24,25], and the difficul-
ties of explaining the uncertainty prevailing in any form
of randomization, [25,26]. While differing options were
appreciated, they might also cause confusion.
“I was blinkered by specialists who thought theirs was
the one to follow!. . .The surgeon said ‘let’s operate’,
he/she was quite bullish. . .’no trial, no options’, ( ). . .
and this was before the SPARE trial was explained tome. . .I naturally thought (operating) was my only
option. . .it was confusing.”
— Mr White - Accepter
Patients’ decision-making is known to be affected by
the initial physician encounter where a special interest
shown by ‘experts’ is perceived, appreciated and advice
duly accepted [13,30,36]. While many of the participants
in this study reiterated this, early advice was often dis-
carded for reasons such as altruism.
“He/she (surgeon) felt that surgery was the most
successful way of combating (the disease) . . .he/she
said the quality of life is much more important (then I
was told about SPARE). . .I was relying on his/her
approval and blessing (to participate). . .( ). . .courtesy
alone apart from his/her expertise. . .because he/she
very kindly had brought me through from my initial
treatment to this stage. . . I very much appreciated (it)
( ). . .but I wanted to help medical science.”
— Mr Marks - Accepter
Busy clinics, run with insufficient resources, are
shown to underlie suboptimal communication and
trial consent [16,38]. There was no dedicated, trial-
specific funding to support recruitment to SPARE
(other than access to National Institute for Health Re-
search (NIHR) funded National Cancer Research Net-
work resources). Moreover, the very structure of
SPARE where patients moved from one treatment to
another, may have accounted for a break in continuity
and trial communication in general. Be that as it may,
clinicians’ preferences and the impact of one careless
comment made by clinicians not involved in the trial
could jeopardize the consent process, especially when
a patient was mindful of quality versus quantity of
life.
“I was convinced that I was going to have my bladder
out because that’s what Mr/Mrs X told me . . .I hadn’t
been told about the trial . . .then I was told that I
could have radiotherapy by a junior doctor. . .I was
confused, it (a change of mind) wasn’t what I
expected of doctors! . . . I saw the consultant who told
me about SPARE . . .by this time my head was full of
this young man/woman telling me that I might not
necessarily need surgery. . .( ) and I am all for that
and I would go for it if it only meant another ( ) 5 or
10 years rather than another 20 years because you
are normal, aren’t you?”
— Mrs Sandy – Decliner
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suggesting that randomization is perceived as an eth-
ical follow on from equipoise or that bias is avoided
through random allocation [36]. ‘Misunderstandings’
were sometimes perceived, however, to relate to a pau-
city of information, too much information or a simple
misconstruing of concepts [19-21]. Often, as in other
studies, randomization was perceived haphazardly as
patients strove to make sense of their involvement in
the trial process while questioning scientific principles
[18,19].
“No, I haven’t got a clue (what randomization means)
. . .it’s lack of information. . .(. . . ) they may at
random. . .oh well ‘we’ll give him a needle in his
arse. . .then we will stick one in his leg’ and just stick
it in at random. . . without reason.”
— Mr Meadow - Decliner
Patients’ preferences and idiosyncratic beliefs about
trial processes had little to do with the reality of SPARE.
Below Mr. Brown, a football supporter and research
advocate, knew that while the comparison between treat-
ments underpins randomization, his reasons for partici-
pation lay in joining ‘the team’ or not, in his quest to ‘up
the numbers’ - not to be allocated treatment. Like
others, he intended to withdraw if his preferred treat-
ment was not forthcoming.
“Randomization?. . . names out of a hat. . .it’s like a draw
for the football. . .you draw out a team, the home
team. . .I am the team that is playing with (SPARE) and
that’s the randomization. . .preferably (computerized). . ..
they press a button and the computer would rattle
around and come up with a name in bright lights with
stars around it . . .( )by joining the group I have added
to the numbers for research purposes ( ) but if I had
been randomised to radiotherapy I would have dropped
out. . .(. . .) I didn’t tell anybody.”
— Mr Brown – Accepter
Bias created through withdrawal post-consent is not
reported in trial literature. However, the impact of with-
drawal on a non-inferiority trial, such as SPARE, can
have a deleterious effect when analyzed on an intention-
to-treat basis [39]. Mr Brown goes on to question the
veracity and validity of SPARE having scrutinized the in-
formation sheet. There was no evidence that his percep-
tions had been challenged.
“ (. . .) Three out of the four (options) that are
available ended the same way with surgery. . .so Idon’t see what randomization has to do with it . . .I
didn’t see after reading the documentation on
SPARE. . . what leaving or staying; what difference it
would make. . .( )randomization wasn’t going to make
any difference to my treatment.”
— Mr Brown – Accepter
The rare belief that withdrawal was impossible indi-
cated that either information sheets had not been appre-
ciated or trialists had not clarified patients’ rights [16].
“(Once randomized) you couldn’t volunteer for the
other (treatment) because you only got that if you
went into the trial and got away with it through
randomization.”
— Mr Hall – Accepter
One of the endpoints of the feasibility study was
adherence to treatment. If it had not been explained
that patients may receive surgery in the SBP group,
adherence to treatment could be compromised. Sev-
eral patients had seemingly not understood that
randomization included the option of surgery. Surgery
was sometimes rightly perceived as the standard
treatment, and randomization as a likelihood of hav-
ing radiotherapy, not as a valid method of comparing
treatments.
“He said ‘you will be selected to continue within the
trial at random. . .there is a chance that the computer
will say ‘you are not going any further in the trial’, at
which stage you will have surgery to have your
bladder removed. (. . .). . .To my limited knowledge it
would be chemotherapy and radiotherapy. . .(. . .) as
treatment for cancer (. . .) I would be picked from the
computer to continue on the trial to have chemotherapy
and radiotherapy or leave ( ) and have surgery.”
— Mr Clarke – Accepter
While patients ‘misunderstood’ or queried trial design
and procedures, their preferred treatment was often per-
ceived as an inevitable outcome. The notion that treat-
ment is individually ‘chosen’ through randomization is
reported elsewhere [10,12,13,18,20]. While patients’
rights may not have been adhered to, nor patients’
beliefs regarding the trial procedures checked or chal-
lenged, the quote below highlights a belief that individ-
ual wishes are realized through the trial process. Indeed,
cynicism was often palpable as doctors were perceived
to collude with patients’ best interests while serving
their own.
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‘randomization’. . .(I got radiotherapy and I wanted
it!). . .they are doing it for their benefit as well as your
benefit and they want their results to be proven.”
— Mr Hall – Accepter
Patients’ understanding of SPARE and the procedures
inherent in randomized trials often appeared to be faulty
but evidence of verification of trial knowledge was con-
spicuously absent. The obvious need for vigilance by tri-
alists was compounded by the ways patients recounted a
separation between themselves and all that the SPARE
trial encompassed.
Inter-relational communication
The patients’ sense of alienation was evident. Feelings of
isolation, loss of control and powerlessness underwrote
involvement in the trial process. Patients’ utterances
were laced with words such as “feeling alone”, “no control”,
“being a guinea pig” and “having no say”. Studies corrob-
orate the importance of ‘a relationship’ between health
professionals and patients and the ways in which ‘bad
communication’ may undermine trust [19,21,40-42] and
prevent participation in trials [40]. Research has, however,
placed ‘good communication’ in the arena of information
giving where full disclosure is advocated [43]. In this
study, as in others, devices such as information leaflets or
hurried verbal information often created rifts between
patients and physicians [36]. Below is a quote from a man
who was ‘in charge’ of his life but nevertheless sought con-
nection - ‘a conversation’ with his doctor.
“He/she (the surgeon) says ‘well life expectancy is
three to five years’ I thought that was out of
order. . .boom boom. . . it all came out . . .It’s a
minefield. . .( ). . .whether he/she (Mr/Mrs X) could
have done that (given diagnosis and prognosis) in a
more caring way. . .or just slung me out in the
corridor I don’t know (. . .) giving me all those leaflets
was a bit of a shock (. . .). . .I wanted a conversation
with my doctor.”
— Mr White – Accepter
While medical progress was anticipated, a significant
number of patients felt undermined, resulting in mis-
trust in the medical enterprise. This was articulated by
patients across the sample, when they failed to under-
stand the ‘language’ of trial procedures.
“Cystoscopy”. . . The name for having your bladder
out? . . .Was it “endoscopy’ or?. . .Yeah. . .I always
worry when people start throwing long words at me. . .they are attempting to confuse me. . .I want to
know it in lay terms like ‘I am having surgery’. . . like
‘the bladder out’. . .the paperwork always related it to
medical terms.”
— Mr Brown – Accepter
Alienation was attributable in part to research over-
load [36], information overload [14], a perceived lack of
information [14] and a sense of coercion [15] undermin-
ing autonomy that, in some cases, affected decision mak-
ing. Patients in this study were sometimes asked to enter
up to four studies. Difficulties regarding assimilation of
information and an obvious disconnection between trial-
ists and their patients were recounted, to the extent that
patients misunderstood their position in the consent
process [14,16,36].
“When I saw ( ) the nurse he/she said about me not
having the treatment and I said well I haven’t refused
it. . .and I didn’t know enough about it . . .all I knew is
( ) you are going as a human guinea pig and they can
do what they like. . .I said “no I didn’t refuse
it’. . .(and) they said ‘yes’. . .but now I said ‘you have
asked me if I am having chemo and now you have
told me that I can’t go in for it anyway so why are you
wasting my time’?. . .( ). . .and I said ‘that (was) a bit of
a waste of time then wasn’t it?. . .I don’t know if he/
she was talking about another treatment. . .I was
asked to do umpteen things and quite honestly I
didn’t understand why or what she was on
about. . .when I said that they said ‘well it’s all written
down there in the info sheet’ and I said ‘yeah, but it’s
not very informative.’ ”
— Mr Meadow – Decliner
Mr Meadow’s ‘muddle’ regarding SPARE and his
consent into the trial was encased in a sense of con-
fused powerlessness, distrust and the ways that infor-
mation received can be perceived as too little, but
could also be construed as too much. In fact, he had
apparently refused SPARE. Just as he articulated a
loss of control despite his para-medical experience,
the ability to hold down a serious job, and the ex-
perience of previous illness, others reiterated a sense
of powerlessness in various ways. Thus, while with-
drawal was often influenced by individual treatment
preferences, a sense of control could be gained by re-
neging on consent.
“(. . .) but the only thing I don’t understand is when
you are pulled out of the computer. . .that’s when the
problem started (I withdrew) ’you will be picked out
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control. . .I got out.”
— Mrs Wall – Accepter/Decliner
Sometimes a sense of loss of control and perceived co-
ercion led to feelings of isolation and disrespect for trial-
ists. In such cases, patient autonomy and ethical practice
were not upheld, [15,16], often due to a perceived lack
of time to consider participation [5,12,13,16,20] during
‘consent discussions’ [12]. Below, Mrs Wall speaks of the
way she perceived herself as sidelined in the clinician’s
hurried quest to obtain consent, but with ineffectual
consequences.
“(. . .) I thought well (the doctor) was pushing me
(to consent) when he/she shouldn’t have
been. . .and that really annoyed me. . .and I saw
him/her twice and each time I thought those
forms are far more important than how I
was. . .he/she is quite abrupt. . .( ) I suppose the
doctor was really talking to my son more than
me ( ) I felt isolated.”
— Mrs Wall – Accepter/Decliner
Perceived ‘coercion’, such as illustrated in the quote
above, was experienced and articulated in various ways.
Below Mr Woods recounts the ways in which a phys-
ician who, no doubt in good faith, intervened in the
wrong context and at the wrong time, portraying a
schism between himself and his professional colleague,
while creating confusion, anxiety and the patient’s need
to establish autonomy.
“On Saturday night, (at home) Dr. Y rung me ( ) the
way he/she spoke to me on the phone I just didn’t
need it. . .I was alright as I was . . .he/she really give
me a bit of an ear bashing. . .’ Mr X shouldn’t have
told you this’. . . I said, ‘ I am only telling you what he
told me’ . . .. I have never seen that doctor again. . ..
He/she said ’you have got to do this. . .you have got to
do that’ and I said ‘well I haven’t got to do
anything. . .if I don’t want to go through with
something’ I said. . .’I won’t go through with it’. . .
(. . . ). . . it really upset me a bit . . ..”
— Mr Woods – Accepter
When researchers fail to deliver cohesive medical mes-
sages, patients become anxious. The demeanor of staff
could be heard to create intra-familial problems and
‘bad’ feelings, including guilt and neglect as a result of
an uneasy alienating atmosphere.“I had a dreadful argument with Peter (son). . .(. . .). . .I
said ‘I have had a phone call from the hospital and
your father is going to have chemotherapy,
radiotherapy’. . .’no he isn’t. . .I have been told
differently’ (he said). . . (. . .) ‘he is going to have the
bladder out’. . .(. . .). . .Confusing. . .I had been
speaking to one Susan and Peter had been speaking
to another Susan ( ). . .. Frank had been picked
(randomized) to have his bladder out and he had said
he didn’t want the bladder out, (because it was
disease-free) he wanted radiotherapy ( ) we could feel
an atmosphere. . .the doctor and the nurse didn’t like
it. . .(. . .). . .he/she didn’t want to speak to me and
Frank felt guilty.”
— Mrs Hanson, wife of Mr Hanson - Accepter/
Decliner
Difficult situations were compensated by ‘good’
accounts concerning staff, corroborating the necessity to
engage in a personal connection with patients if only to
enable a sense of inclusion in the hospital process.
“If I am going to give anybody any special praise. . .
. . . the receptionist at the chemo clinic. . .he/she was
pleasant, she would laugh and have a joke. He/she
was well organised,. . .(. . .) absolutely superb. . .it
makes the biggest difference . . .he/she made me
welcome.”
— Mr Brown – Accepter
Favorable perceptions of personnel are pivotal to creat-
ing and maintaining trust and facilitating connectedness
and mutual respect [35,36,41,42] leading to a sense of
cohesion and autonomy. Previous work has focused on
the ways in which hospital personnel give emotional care
that is ‘hidden’ and seldom given credence [44]. Just as
health workers are involved in unspoken emotional
‘work’, patients too may be immersed in ‘working
the system’.
Administration as communication
Although not the focus of this research, patients spon-
taneously indicated the need to ‘work’ their way around
NHS waiting times and hospital administration. There is
little in the literature that indicates the impact of this on
patients’ trial behavior. Patients in this study often criti-
cized their need to ‘work’ against ‘bad administration’,
sometimes affecting trial decisions. This did not appear
to rely on patient characteristics.
The majority of patients in this study responded
quickly to symptoms. While there is evidence that this
sense of urgency is mirrored by GPs and tertiary
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engendered anxiety, anger and scepticism while UK
DOH guidelines [46] were acknowledged and criticized.
Mr Hall recounts the way in which long waits were fol-
lowed by the availability of instant treatment in the
SPARE trial, determining his decision to consent.
“the whole handling (. . .) was crap. . .um the issue of
getting to the hospital, getting the cystoscopy
done. . .that was the maximum time. . . I went to (the
doctor) in June and we didn’t do the camera until
September ( ) we don’t start the treatment until
December so its six months. . .( ) when I have got
something wrong with me because I am bleeding (and
I’ve been told that my tumor is aggressive). . .to wait
for any action to take place is not right . . .I still feel
angry. . .they are playing lotto with your life. . .it’s all
down to the targets and the way things are structured
. . .(. . .) then I met Dr Y (who told me about SPARE)
and I said ‘when can you start? ’We can start the
chemo on Monday’. ‘OK , that was my main reason
for going for the trial.”
— Mr Hall – Accepter
While patients were loath to criticize, difficulty at the
hands of administrators was evident. Below, Mr Plane
explains the ‘muddle’ he faced, and the potential to
jeopardize trust and respect, if not participation.
“we would like you (to come) next Tuesday 15th and
Tuesday is the 14th. . .and so you would have to ring
afterwards and say ‘do you want to see me on the
Monday or the Tuesday’. . .and the other thing, I was
half way through my chemo cycle and I ( ) got a call
from Elsewhere hospital. . .‘can you make it down here
at 1 o’clock next Tuesday?’ and I said ‘yes why’?. . .he/
she said ‘because doctor what’s-his-name is down
here, and we do your cystoscopy’. . .so I thought ‘oh
well right’. . .in between that and going I had a word
with my . . .oncologist and he/she went up the wall.
‘Why (. . .) half way through your treatment?. . .There
is no point’. . .he had told me the 15th March, not the
15th of February. . .I would say to others ‘you have got
to keep a weather eye open on what’s going on’ . . . I
got three letters . . . two posted on the same day, one
the day after giving me three different appointments
to see the oncologist . . .( ). . .it might make others
anxious!”
— Mr Plane – Decliner
The complicated logistical problems inherent in the
patient pathway of SPARE (Figure 2) meant that somepatients spoke with multiple physicians and traveled
from the diagnosing hospital to another center for
definitive treatment [47]. This jeopardized communica-
tion and could cause treatment decisions to be arrived
at covertly.
“My treatment extends over four different
counties. . .four hospitals. . .dealing with me ). . .. . .it’s
difficult to know what hospital is doing what. . .if all
the procedures could have been carried out in one
area. . .I would see the anesthetist who was not going
to be my anesthetist ( ) . . .I had one doctor’s name on
the admissions letter. . .one surgeon’s name on (it). . .I
was interviewed by another surgeon, on my discharge,
there was a third doctor’s name and then a fourth
doctor’s name ( ) and I wouldn’t have chosen
radiotherapy because the nearest radiotherapy is
(elsewhere) which is about an hour and half ’s drive
for a 10-minute treatment. . .’
— Mr Brown – Accepter
Mr Brown, like others, seemed unable to discuss his
misgivings with clinicians, but demonstrated the way in
which patients wish to contribute to science, despite it
being perceived as a context filled with ambiguity and
confusion.
Discussion
This study highlights the perceptions of patients invited
to enter a complex intervention trial that was curtailed
because of low recruitment. While it was not always
possible to make obvious links between trial procedures
and patient participation, qualitative data have shown
how sub-optimal communication in all its guises leads to
confusing messages, alienation of patients and ground-
less decision-making, potentially compromising trial
validity and ethical conduct.
Despite every effort to conduct a high quality trial,
there was an inherent difficulty in managing a ‘high
stake’ randomized trial such as SPARE where surgery
was compared with radical radiotherapy. Such a study
did not lend itself to explaining ‘equipoise’ and ‘random
allocation’, the former being particularly difficult for clin-
icians to explain and patients to accept. Physicians’ pre-
ferences and the difficulties of ‘equipoise’ have been
shown to undermine confidence and optimal recruit-
ment [5,11,24,36,47], and challenge the traditional roles
of doctor and patient [23]. Furthermore, an integration
of what have been perceived as contrasting and compet-
ing roles of researcher and physician is required [23].
This study suggests that a debate as to whether RCTs
are appropriate in the evaluation of complex interven-
tions may be fruitful. Alternative strategies that take
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to provide a means of assessing the efficacy of com-
plex treatments.
An aim of SPARE was to assess recruitment rates in a
multi-center context. This took place in the absence of
dedicated trial specific resources at the centers involved.
Thus, as with most non-commercially funded RCTs in
the UK, there was little leverage with which to influence
the trial behavior of the many health professionals work-
ing with SPARE, although problems and suggested solu-
tions were disseminated regularly. Our data reflected
problems reported in previous studies. This raises ques-
tions about how research into trial recruitment is disse-
minated within modern health services and how trialists
can be informed of and deliver best practice [5,12].
Structural issues and logistical problems inherent in
the NHS are likely to have impacted on patient and
physician trial behavior. The complicated treatment
pathway in the SPARE trial (Figure 2) seems to have
prohibited personnel from giving comprehensive expla-
nations and consistent support regarding concepts and
trial procedures. This helps to explain patients’ observed
confusion and potentially uninformed consent, not with-
standing that SPARE had to involve non-trial staff in the
recruitment process who may have been unwilling [48]
and/or less skilled at approaching patients and explain-
ing trial concepts, such as equipoise.
Our findings are replicated in a further SPARE qualita-
tive study that was conducted in real time [47]. Parama-
sivan et al. revealed that trialists had difficulty in
articulating the complex trial design, leading to a palp-
able breakdown in communication. Information was
given in complicated and erroneous terms, reflecting
physicians’ preferences. We propose that attention be
focused on training trialists who are involved in recruit-
ment to complicated trials, both in terms of communica-
tion processes and on the assimilation of complex trial
pathways experienced as a consequence of the current
structures of the NHS. The ProtecT study [11] has
demonstrated how this can be achieved in a similarly
complex RCT involving surgery.
Participants in SPARE seemed to lack comprehension
of trial procedures but this was not premised on a deficit
model [13]. Study participants indicated that their
understanding of randomization and equipoise were not
necessarily verified. Both concepts are highly complex
and require thought about how their meaning is com-
municated [37,40]. However, simple provision of clear
factual information is often not sufficient to ensure
‘informed consent’ [5,13,30,36]. Patients in this study
and others are known to interpret particular terms dif-
ferently from what is actually said by clinicians [49,50],
highlighting the importance of verification to achieve
valid informed consent. As our data show, even ifpatients understand the scientific perspective, they may
not accept its validity or the offer to participate in trials.
They can rely instead on other factors, such as their own
preferences associated with their everyday lives, both
perspectives being rational and reasonable in their
own terms. [38,49,50]. Research that investigates individ-
ual encounters between patients and their doctors
remains essential.
Sub-optimal communication, including interpersonal
interaction between trialists and patients, may have been
a major factor in decision-making [16], sometimes lead-
ing to invalid consent. It should be borne in mind that
patients enter trials with an innocence and fear that may
be difficult for ‘expert’ trialists to comprehend [16]. This
and the perceived inequality of levels of status, know-
ledge and power in the doctor/patient relationship [51]
may obstruct a close alliance [42] and the means to clar-
ify trial procedures. Our data show that patients felt
undermined and separated from the medical enterprise.
We suggest that patients may wish for a mode of caring
that goes beyond ‘empathic information giving’ [52].
This raises questions as how best to formulate this inter-
action. We suggest it would involve physicians facilitat-
ing a context in which patients have closer contact and a
‘relationship’ with health personnel that includes trust
and respect [41,42,53,54], together with a recognition
that ill people experience vulnerability, and a need to
feel ‘attached’ and included [41,42,53,54]. We have
observed that the most engaged patients professed the
most personal interaction with trial and other staff, lead-
ing to an enhanced patient experience. These factors are
pertinent in the context of all RCTs, where ethical con-
siderations incorporate the need for obtaining valid,
informed and unbiased consent [17] and where the con-
nectedness we speak of may help to restore autonomy
and enhance recruitment.Limitations of the qualitative study
Our data apply to patients who are largely men of white
ethnicity who have been invited to consent to a complex
intervention trial which gave rise to problems that may
not be encountered in straightforward RCTs. Our find-
ings rely on patients’ perceptions and not the ongoing
reality of a trial. We did not systematically investigate
factors such as training levels or work overload of re-
search staff, all of which may have impacted on our find-
ings [38]. Qualitative studies that examine the ways
trialists interact with potential participants in ‘real time’
may produce valuable insights [11]. Such a study was
instigated midway through SPARE [47].
Despite these caveats, patients’ perceptions are import-
ant. The literature vindicates our findings, making it
possible to extrapolate them to other RCTs.
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This study highlights the difficulty of providing balanced
and clear trial information within the UK health system,
despite the best intentions of research staff at participat-
ing sites. We suggest that not only is training made
available to potential trialists but that consideration
might be given to possible alternatives to randomization
where complex interventions are being tested. Involve-
ment of multiple professionals can impact on patient sup-
port, including communication processes with patients
who are considering participation in RCTs, leading us to
question the ‘deficit’ model of patients’ understanding and
behavior. It is suggested that health professionals consider
facilitating a context in which patients feel fully included
in the trial enterprise.
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